1,4,7,10-TETRAAZACYCLODODECANE-1,4,7-TRIACETIC ACID, 10-(2-(((4-(((3-((2R,5S,8S,14R)-5-(3-((AMINOIMINOMETHYL)AMINO)PROPYL)-14-((4-HYDROXYPHENYL)METHYL)-1-METHYL-8-(2-NAPHTHALENYLMETHYL)-3,6,9,12,15-PENTAOXO-1,4,7,10,13-PENTAAZACYCLOPENTADEC-2-YL)PROPYL)AMINO)CARBONYL)PHENYL)METHYL)AMINO)-2-OXOETHYL)-
Erdheim-Chester Disease
Memorial Sloan Kettering Cancer Centerprotein_peptideEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Erdheim-Chester Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cobimetinib Cancer Research UK | Phase 2/3 | B |
Dabrafenib Cancer Research UK | Phase 2/3 | B |
gsk1120212 Cancer Research UK | Phase 2/3 | B |
VEMURAFENIB Cancer Research UK | Phase 2/3 | CCC |
hlx208 Shanghai Henlius Biotech | Phase 2 | CCC |
View all 10 →
Same molecule, other indications
1,4,7,10-TETRAAZACYCLODODECANE-1,4,7-TRIACETIC ACID, 10-(2-(((4-(((3-((2R,5S,8S,14R)-5-(3-((AMINOIMINOMETHYL)AMINO)PROPYL)-14-((4-HYDROXYPHENYL)METHYL)-1-METHYL-8-(2-NAPHTHALENYLMETHYL)-3,6,9,12,15-PENTAOXO-1,4,7,10,13-PENTAAZACYCLOPENTADEC-2-YL)PROPYL)AMINO)CARBONYL)PHENYL)METHYL)AMINO)-2-OXOETHYL)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →